TENXTenax Therapeutics, Inc.

Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.

Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody

The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA. Key Investor TakeawaysTenax Therapeutics (NASDAQ:TENX) said its Phase 3 LEVEL trial of TNX-103 did not meet the primary 6-minute walk distance endpoint or the key secondary KCCQ symptom endpoint.

Shares of Tenax Therapeutics and Sionna Therapeutics tumbled Monday after the biotechs revealed separate late-stage trial failures. Tenax stock fell nearly 90% after a Phase 3 trial of its experimental heart-failure pill failed to help patients walk farther than those on a placebo.

The biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.

Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fresh clues on the Federal Reserve’s interest rate path.

The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.